

EVERYONE KNEW MY FATHER. SADLY, HE DID NOT REMEMBER ME.

Denis's father, Henri Richard, also known as the Pocket Rocket, was the captain of the Montreal Canadiens. After a long and successful hockey career that included winning eleven Stanley cups, Henri Richard developed Alzheimer's disease. Watching Henri gradually fade away was an extremely painful experience for Denis and the extended Richard family, as it is for the millions of Canadians who have lost a loved one to Alzheimer's.


At the Douglas Institute, our mission is simple. Discover answers, find solutions, identify better prevention strategies, and ultimately eliminate the suffering experienced by those afflicted with Alzheimer's disease and their families. Our world class team is leading multiple research projects dedicated to understanding the causes of Alzheimer's and developing tangible prevention strategies and treatments.

Alzheimer's disease is the most alarming chronic disease for Canadians over 55 and among the top six causes of deaths in North America.




BUILDING HOPE
The movement

Douglas
FOUNDATION
FOUNDATION



ALZHEIMER'S DISEASE

Our current situation



Today, more than 500,000 Canadians suffer from a neurocognitive disorder. Alzheimer's disease is the most common form of dementia, representing more than 60% of cases in the country according to the Alzheimer Society of Canada.

36 million

Number of people affected by Alzheimer's disease globally.

60%

Alzheimer's disease represents more than 60% of neurocognitive disorder cases in Canada.

900,000

Number of Canadians who will suffer from a neurocognitive disorder in 2030.

The Douglas is at the forefront of research, **prevention** and treatment of **Alzheimer's disease** as well as **dementia**. Our researchers collaborate with leading international experts and have been part of many **important clinical discoveries** that helped to **build hope** for Canadians suffering from these neurodegenerative diseases.

To learn more about our services, visit fondationdouglas.qc.ca

Follow us on social media



Douglas
FONDATION
FONDATION

ALZHEIMER'S DISEASE

A global approach for Alzheimer's disease and dementia



Research/Prevention



Patient Care

The Douglas Institute's integrated approach makes it possible to identify **early markers** of Alzheimer's disease and dementia. Our **advanced techniques** allow us to assess the **best ways to process** and modify the trajectory of these devastating neurological diseases.



A multidisciplinary approach relying on cutting-edge technology that allows our researchers to map silent and inconspicuous parts of the disease.



A cohort study of over 425 asymptomatic subjects with a parental history of Alzheimer's disease with the goal of identifying the biological markers associated with the onset of the disease.



Clinical trials with pharmacological agents capable of modulating biological markers to stimulate protection factors against Alzheimer's disease.

Did you know?

Our researchers are interested in the early detection of dementia in the elderly, especially different types of biological and psychological markers associated with it. Their research activities focus on the study of the onset and evolution of Alzheimer's disease and related dementias, as well as the identification of new ways to treat and prevent neurodegenerative diseases.



BUILDING HOPE
The movement

Douglas
FOUNDATION
FOUNDATION

ALZHEIMER'S DISEASE

Specialists



Pedro Rosa-Neto

Dr. Pedro Rosa-Neto, PhD, is a clinical neurologist and director of the Translational Neuroimaging Laboratory at the Douglas Research Centre. He is particularly interested in the structural changes that occur in the brain as a result of neurodegenerative disease such as Alzheimer's disease.

Pedro's research projects make use of brain imaging techniques, particularly through Magnetic Resonance Imaging (MRI), for the observation and measurement of changes in the structures of the brain. His laboratory develops neuroimaging techniques and analytical frameworks that allow advanced modeling of neurodegenerative processes.

Pedro and his team collaborate with a vast network of laboratories to train emerging scientists in neuroimaging and one day being able to put a stop to neurodegenerative diseases.



Simon Ducharme

Dr. Simon Ducharme, PhD, works as a neuropsychiatrist at the Douglas Mental Health University Institute; his clinical field of expertise is frontotemporal dementia.

Simon and his team's research uses advanced structural brain-imaging techniques to study changes in brain development from childhood to old age, and their impact on behavior in terms of health and psychopathology.

Simon is Chairman of the American Neuropsychiatric Association Research Committee and conducts numerous clinical trials in Alzheimer's disease and dementia. He is convinced that it is by accelerating discoveries and the best preventive measures to fight against neurodegenerative diseases that it will be possible to build hope for those who are affected.



Sylvia Villeneuve

Sylvia Villeneuve, PhD, and her team of high-tech experts use multimodal neuroimaging techniques to investigate brain changes associated with age and neurodegenerative disorders such as Alzheimer's disease.

Sylvia is a leader of the Stop-AD program, a vast and unique research that recruits people who are at higher risk of developing Alzheimer's disease. Following these participants helps to better understand the various stages of the progression of the disease.

The Stop-AD program generates an incredible wealth of information that demonstrates how certain lifestyles can have an impact in order to slow the onset of AD. Sylvia's team believes in the value of this knowledge which is a cornerstone to build hope for people who are suffering.



Judes Poirier

Judes Poirier, PhD, CQ, is the director of the Molecular Neurobiology Unit and the Research Program on Aging, Cognition and Alzheimer's disease at the Douglas Research Centre.

His teams' pioneering work has led to the successful identification of several potential pharmacological targets. He recently captured the attention of the population through a study using specially trained dogs that were paired with Alzheimer's patients still living at home.

Judes firmly believes that it is possible to build hope for people suffering from this terrible disease thanks to the research that is carried out at the Douglas.